We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Implantation of Peripheral Stem Cells in Patient With Ischemic Cardiomyopathy (ISCIC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2012 by Iurii Kozlov, Odessa National Medical University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01615250
First Posted: June 8, 2012
Last Update Posted: June 11, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Iurii Kozlov, Odessa National Medical University
  Purpose
This is a randomized study of efficiency and safety of intramyocardial implantation of peripheral mononuclear cells with high concentration of CD34+ stem cells in patients with myocardial ischemia after preparatory course of shock - wave therapy.

Condition Intervention Phase
Heart Failure Biological: Intramyocardial implantation of stem cells Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study to Evaluate the Efficacy and Safety of Intramyocardial Implantation of Peripheral Mononuclear Cells With CD34+ Stem Cells in Patient With Ischemic Cardiomyopathy After Preparatory Course of Shock - Wave Therapy

Resource links provided by NLM:


Further study details as provided by Iurii Kozlov, Odessa National Medical University:

Primary Outcome Measures:
  • Change in global left ventricular ejection fraction and regional wall motion score index [ Time Frame: 6 and12 months ]
    Change in global left ventricular ejection fraction and regional wall motion score index.


Secondary Outcome Measures:
  • Incidence of the major adverse cardiac events [ Time Frame: 6 and 12 months ]
    Incidence of the major adverse cardiac events.


Estimated Enrollment: 50
Study Start Date: January 2012
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Standard therapy
Treatment with standard therapy. Cardiospec shock-wave therapy
Active Comparator: Stem cells
Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.
Biological: Intramyocardial implantation of stem cells
Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with ischemic cardiomyopaty and HF II-IV NYHA class
  • MI more than 6 months before the study
  • LVEF less than 35%
  • Absence effect of coronary revascularization during 6 months
  • Optimal pharmacological therapy no less than 8 weeks
  • Heart transplantation is contraindicated
  • Patients with implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D)
  • Patients giving informed consent

Exclusion Criteria:

  • Acute coronary syndrome
  • Coronary revascularization less than 6 months
  • Patients requiring surgical correction of post-MI aneurism
  • LV wall thickness less than 5 mm in site of possible injection
  • Patients with CRT implanted within 3 month before cells injection
  • Clinically significant associated diseases
  • Active oncology desiase
  • Pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01615250


Contacts
Contact: Iurii I Karpenko, Dr, PhD +38048750113 ext +38048750113 arcard2@gmail.com

Locations
Ukraine
Odessa Regional Clinical Hospital Recruiting
Odessa, Ukraine, 65025
Contact: Iurii I Karpenko, Dr, PhD    +380487500115 ext +380487500115    arcard2@gmail.com   
Sponsors and Collaborators
Odessa National Medical University
Investigators
Principal Investigator: Iurii I Karpenko, Dr, PhD Odessa National Medical University
  More Information

Responsible Party: Iurii Kozlov, Dr., PhD Iurii I Karpenko, Odessa National Medical University
ClinicalTrials.gov Identifier: NCT01615250     History of Changes
Other Study ID Numbers: ISCIC-2012
First Submitted: June 6, 2012
First Posted: June 8, 2012
Last Update Posted: June 11, 2012
Last Verified: June 2012

Additional relevant MeSH terms:
Heart Failure
Cardiomyopathies
Heart Diseases
Cardiovascular Diseases